Athersys PE Ratio 2006-2021 | ATHX

Current and historical p/e ratio for Athersys (ATHX) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Athersys PE ratio as of October 26, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Athersys PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-26 1.18 0.00
2021-06-30 1.44 $-0.45 0.00
2021-03-31 1.80 $-0.45 0.00
2020-12-31 1.75 $-0.42 0.00
2020-09-30 1.95 $-0.37 0.00
2020-06-30 2.76 $-0.34 0.00
2020-03-31 3.00 $-0.30 0.00
2019-12-31 1.23 $-0.29 0.00
2019-09-30 1.33 $-0.31 0.00
2019-06-30 1.68 $-0.30 0.00
2019-03-31 1.50 $-0.19 0.00
2018-12-31 1.44 $-0.18 0.00
2018-09-30 2.10 $-0.21 0.00
2018-06-30 1.97 $-0.20 0.00
2018-03-31 1.83 $-0.31 0.00
2017-12-31 1.81 $-0.29 0.00
2017-09-30 2.06 $-0.28 0.00
2017-06-30 1.51 $-0.29 0.00
2017-03-31 1.71 $-0.31 0.00
2016-12-31 1.53 $-0.19 0.00
2016-09-30 2.13 $-0.05 0.00
2016-06-30 2.17 $-0.06 0.00
2016-03-31 2.25 $-0.03 0.00
2015-12-31 1.03 $-0.25 0.00
2015-09-30 1.10 $-0.37 0.00
2015-06-30 1.21 $-0.37 0.00
2015-03-31 2.88 $-0.36 0.00
2014-12-31 1.58 $-0.35 0.00
2014-09-30 1.39 $-0.42 0.00
2014-06-30 1.79 $-0.44 0.00
2014-03-31 3.24 $-0.51 0.00
2013-12-31 2.50 $-0.54 0.00
2013-09-30 1.64 $-0.46 0.00
2013-06-30 1.66 $-0.48 0.00
2013-03-31 1.68 $-0.50 0.00
2012-12-31 1.06 $-0.49 0.00
2012-09-30 1.39 $-0.60 0.00
2012-06-30 1.61 $-0.58 0.00
2012-03-31 1.55 $-0.59 0.00
2011-12-31 1.73 $-0.60 0.00
2011-09-30 1.76 $-0.53 0.00
2011-06-30 2.71 $-0.62 0.00
2011-03-31 2.84 $-0.64 0.00
2010-12-31 2.47 $-0.60 0.00
2010-09-30 3.05 $-0.75 0.00
2010-06-30 2.91 $-0.74 0.00
2010-03-31 3.10 $-0.76 0.00
2009-12-31 4.13 $-0.81 0.00
2009-09-30 1.22 $-0.80 0.00
2009-06-30 0.88 $-0.86 0.00
2009-03-31 0.90 $-0.90 0.00
2008-12-31 0.45 $-0.96 0.00
2008-09-30 1.74 $-0.96 0.00
2008-06-30 2.45 $-0.72 0.00
2008-03-31 3.75 $-0.50 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.267B $0.001B
Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an `off the shelf` allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86